Volume | 629,434 |
|
|||||
News | (3) | ||||||
Day High | 23.87 | Low High |
|||||
Day Low | 22.70 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Prothena Corporation PLC | PRTA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
23.31 | 22.70 | 23.87 | 23.03 | 23.54 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
11,009 | 629,434 | $ 23.00 | $ 14,474,831 | - | 19.65 - 79.38 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:19:59 | 1 | $ 21.05 | USD |
Prothena Corporation PLC Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.24B | 53.72M | - | 91.37M | -147.03M | -2.74 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Prothena News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PRTA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 20.59 | 24.20 | 20.26 | 22.68 | 602,367 | 2.44 | 11.85% |
1 Month | 22.28 | 24.20 | 19.65 | 21.75 | 519,862 | 0.75 | 3.37% |
3 Months | 27.76 | 31.03 | 19.65 | 25.14 | 584,036 | -4.73 | -17.04% |
6 Months | 36.20 | 41.545 | 19.65 | 30.90 | 728,279 | -13.17 | -36.38% |
1 Year | 78.50 | 79.38 | 19.65 | 41.25 | 619,255 | -55.47 | -70.66% |
3 Years | 24.60 | 79.749 | 19.65 | 45.17 | 530,581 | -1.57 | -6.38% |
5 Years | 10.52 | 79.749 | 6.44 | 36.99 | 428,048 | 12.51 | 118.92% |
Prothena Description
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). |